Before you sell to, join or invest in Aligos Therapeutics, Inc.
MentionFox check on Aligos Therapeutics, Inc.: only 1 source on file so far (checked 5 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/aligos-therapeutics-inc-form-d-25000001
Check Aligos Therapeutics, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
What do you want to do about Aligos Therapeutics, Inc.?
Based on the record MentionFox holds for this company. No flag is not a clearance.
Aligos Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-02-28.
Aligos Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on February 28, 2025. The filing reports $105M sold. Its industry group is Biotechnology. It names Lawrence Blatt (President and Chief Executive Officer), Lesley Calhoun (Executive Vice President, Chief Operating Officer and Chief Financial Officer), K. Hirth (Director) (SEC Form D, February 28, 2025).
Is this your company?
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Sell to companies like Aligos Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-02-28 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Aligos Therapeutics, Inc.
Free to see. No signup.
Get an email when Aligos Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Aligos Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Aligos Therapeutics, Inc. →Get the full cited report on Aligos Therapeutics, Inc.
What the filing shows about Aligos Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Aligos Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Aligos Therapeutics, Inc.'s address as One Corporate Dr., 2nd Floor, South San Francisco, CA 94080.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Aligos Therapeutics, Inc. See pricing
Aligos Therapeutics, Inc. is a registered filer with the SEC (CIK 1799448) and has filed since 2023-11-07. 2 filings are on record, the latest on 2025-02-28.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Aligos Therapeutics, Inc.'s Form D of 2025-02-28 names Lawrence Blatt, Lesley Calhoun, K. Hirth and 7 more as its officers, directors or promoters.
Its new offerings report $197.15M sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 765 filings in Biotechnology, totalled by week.
On the filing as: Executive Officer, Director.
Lawrence Blatt is named as President and Chief Executive Officer on the Form D that Aligos Therapeutics, Inc. filed with the SEC on 28 February 2025, one of 10 people that filing names.
On the filing as: Executive Officer.
Lesley Calhoun is named as Executive Vice President, Chief Operating Officer and Chief Financial Officer on the Form D that Aligos Therapeutics, Inc. filed with the SEC on 28 February 2025, one of 10 people that filing names.
K. Hirth is named as Director on the Form D that Aligos Therapeutics, Inc. filed with the SEC on 28 February 2025, one of 10 people that filing names.
Margarita Chavez is named as Director on the Form D that Aligos Therapeutics, Inc. filed with the SEC on 28 February 2025, one of 10 people that filing names.
Carole Nuechterlein is named as Director on the Form D that Aligos Therapeutics, Inc. filed with the SEC on 28 February 2025, one of 10 people that filing names.
James Scopa is named as Director on the Form D that Aligos Therapeutics, Inc. filed with the SEC on 28 February 2025, one of 10 people that filing names.
Bridget Martell is named as Director on the Form D that Aligos Therapeutics, Inc. filed with the SEC on 28 February 2025, one of 10 people that filing names.
Heather Preston is named as Director on the Form D that Aligos Therapeutics, Inc. filed with the SEC on 28 February 2025, one of 10 people that filing names.
Julian Symons is named as Executive Officer on the Form D that Aligos Therapeutics, Inc. filed with the SEC on 28 February 2025, one of 10 people that filing names.
Hardean Achneck is named as Executive Officer on the Form D that Aligos Therapeutics, Inc. filed with the SEC on 28 February 2025, one of 10 people that filing names.
10 people named on the filing — 4 holding an executive role and 6 as directors only.
Named as of the 2025-02-28 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Aligos Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Aligos Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aligos Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Aligos Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Aligos Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Aligos Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in San Francisco Bay Area
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/aligos-therapeutics-inc-form-d-25000001